Advisory Committees; Tentative Schedule of Meetings for 2010, 69119-69122 [E9-30973]
Download as PDF
<![CDATA[
Federal Register / Vol. 74, No. 249 / Wednesday, December 30, 2009 / Notices
mstockstill on DSKH9S0YB1PROD with NOTICES
amended (5 U.S.C. Appendix 2) notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The purpose of this
meeting is to evaluate requests for
preclinical development resources for
potential new therapeutics for the
treatment of cancer. The outcome of the
evaluation will provide information to
internal NCI committees that will
decide whether NCI should support
requests and make available contract
resources for development of the
potential therapeutic to improve the
treatment of various forms of cancer.
The research proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material and
personal information concerning
individuals associated with the
proposed research projects, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel, NCI
Experimental Therapeutics Program (NExT)
Cycle 2.
Date: January 13, 2010.
Time: 8:30 a.m.–4:30 p.m.
Agenda: To evaluate the NCI Experimental
Therapeutics Program Portfolio.
Place: National Institutes of Health,
Building 31A—Conference Room 8A28, 31
Center Drive, Bethesda, MD 20817.
Contact Person: Dr. Barbara Mroczkowski,
Executive Secretary, NCI Experimental
Therapeutics Program, National Cancer
Institute, NIH, 31 Center Drive, Room 3A44,
Bethesda, MD 20892. (301) 496–4291.
mroczkowskib@mail.nih.gov.
This notice is being published less than 30
days prior to the meeting due to scheduling
conflicts.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: December 22, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–31012 Filed 12–29–09; 8:45 am]
BILLING CODE 4140–01–P
VerDate Nov<24>2008
19:01 Dec 29, 2009
Jkt 220001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel, NCI
Discovery and Development P01.
Date: February 2–3, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott, 5151 Pooks Hill
Road, Bethesda, MD 20814.
Contact Person: Sergei Radaev, PhD.,
Scientific Review Officer, Resources And
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, 6116 Executive Blvd., Room 8113,
Rockville, MD 20852, 301–435–5655,
sradaev@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel,
Epidemiology, Prevention, Control &
Population Sciences.
Date: February 9–11, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, Montgomery County
Conference Center Facility, 5701 Marinelli
Road, North Bethesda, MD 20852.
Contact Person: Wlodek Lopaczynski,
M.D., PhD, Scientific Review Officer,
Research Programs Review Branch, Division
of Extramural Activities, National Cancer
Institute, 6116 Executive Blvd., Room 8131,
Bethesda, MD 20892, 301–594–1402,
lopacw@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, Molecular
Oncology—Basic, Translational, and Clinical
Studies.
Date: February 9–11, 2010.
Time: 5 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD.
Contact Person: David G. Ransom, PhD,
Scientific Review Officer, Research Programs
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
69119
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
6116 Executive Blvd., Rm. 8133, Bethesda,
MD 20892–8328, 301–451–4757,
david.ransom@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, SPORE in
Gynecologic, Breast, and Skin Cancers.
Date: February 17–19, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, Bethesda,
MD.
Contact Person: Caron A. Lyman, PhD,
Scientific Review Officer, Research Programs
Review Branch, Division of Extramural
Activities, National Cancer Institute, 6116
Executive Blvd, Room 8119, Bethesda, MD
20892–8328, 301–451–4761,
lymanc@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, SPORE in
Brain, Leukemia, Myeloma, Sarcoma,
Esophageal, GI, HN, and Pancreatic Cancers.
Date: February 17–19, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Shamala K. Srinivas, PhD.,
Scientific Review Officer, Research Programs
Review Branch, Division of Extramural
Activities, National Cancer Institute, 6116
Executive Boulevard, Room 8123, Bethesda,
MD 20892, 301–594–1224, ss537t@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: December 21, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–30923 Filed 12–29–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0664]
Advisory Committees; Tentative
Schedule of Meetings for 2010
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing a
tentative schedule of forthcoming
meetings of its public advisory
E:\FR\FM\30DEN1.SGM
30DEN1
69120
Federal Register / Vol. 74, No. 249 / Wednesday, December 30, 2009 / Notices
committees for 2010. During 1991, at the
request of the Commissioner of Food
and Drugs (the Commissioner), the
Institute of Medicine (the IOM)
conducted a study of the use of FDA’s
advisory committees. In its final report,
one of the IOM’s recommendations was
for the agency to publish an annual
tentative schedule of its meetings in the
Federal Register. This publication
implements the IOM’s recommendation.
FOR FURTHER INFORMATION CONTACT:
Teresa L. Hays, Advisory Committee
Oversight and Management Staff (HF–
4), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857,
301–827–1220.
SUPPLEMENTARY INFORMATION: The IOM,
at the request of the Commissioner,
undertook a study of the use of the
FDA’s advisory committees. In its final
report in 1992, one of the IOM’s
recommendations was for FDA to adopt
a policy of publishing an advance yearly
schedule of its upcoming public
advisory committee meetings in the
Federal Register; FDA has implemented
this recommendation. The annual
publication of tentatively scheduled
advisory committee meetings will
provide both advisory committee
members and the public with the
opportunity, in advance, to schedule
attendance at FDA’s upcoming advisory
committee meetings. Because the
schedule is tentative amendments to
this notice will not be published in the
Federal Register. However, changes to
Committee Name
the schedule will be posted on the FDA
advisory committees’ Internet site
located at https://www.fda.gov/Advisory
Committees/default.htm. FDA will
continue to publish a Federal Register
notice 15 days in advance of each
upcoming advisory committee meeting,
to announce the meeting (21 CFR 14.20).
The following list announces FDA’s
tentatively scheduled advisory
committee meetings for 2010. You may
also obtain up-to-date information by
calling the Advisory Committee
Information Line, 1–800–741–8138
(301–443–0572 in the Washington, DC
area) and use the appropriate
Information Line Code for the
committee in which you are interested.
Tentative Date of Meeting(s)
Advisory Committee 10-Digit Information Line
Code
OFFICE OF THE COMMISSIONER
Pediatric Advisory Committee
March 22, June 21–22, September 20–21, December 6–7
8732310001
Risk Communication Advisory Committee
February 25–26, May 6–7, August 19–20, November 8–9
8732112560
Science Board to the Food and Drug Administration
February 22, May 17, August 16, November 15
3014512603
Allergenic Products Advisory Committee
April 30, October 26
3014512388
Blood Products Advisory Committee
April 12–13, July 26–27, November 18–19
3014519516
Cellular, Tissue and Gene Therapies Advisory Committee
To be announced
3014512389
Transmissible Spongiform Encephalopathies Advisory
Committee
To be announced
3014512392
Vaccines and Related Biological Products Advisory Committee
February 22, May 19–20, September 15–16, November 17–
18
3014512391
Anesthetic and Life Support Drugs Advisory Committee
January 28, April 22, April 23
3014512529
Anti Infective Drugs Advisory Committee
August and October dates To be announced
3014512530
Antiviral Drugs Advisory Committee
To be announced
3014512531
Arthritis Advisory Committee
May dates To be announced
3014512532
Cardiovascular and Renal Drugs Advisory Committee
January 11, March 1, April dates to be announced, July 28,
July 29, December 8, December 9
3014512533
Dermatologic and Ophthalmic Drugs Advisory Committee
To be announced
3014512534
Drug Safety and Risk Management Advisory Committee
To be announced
3014512535
Endocrinologic and Metabolic Drugs Advisory Committee
January 12, January 13, February 24, May 26–27
3014512536
Gastrointestinal Drugs Advisory Committee
February 23, November dates to be announced
3014512538
Nonprescription Drugs Advisory Committee
To be announced
3014512541
Oncologic Drugs Advisory Committee
February 10, May 4, May 5, July 20, July 21, September 1,
September 2, December 1, December 2
3014512542
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH
mstockstill on DSKH9S0YB1PROD with NOTICES
CENTER FOR DRUG EVALUATION AND RESEARCH
VerDate Nov<24>2008
19:01 Dec 29, 2009
Jkt 220001
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
E:\FR\FM\30DEN1.SGM
30DEN1
Federal Register / Vol. 74, No. 249 / Wednesday, December 30, 2009 / Notices
Committee Name
Tentative Date of Meeting(s)
69121
Advisory Committee 10-Digit Information Line
Code
Peripheral and Central Nervous System Drugs Advisory
Committee
March 23, March 24, June dates to be announced
3014512543
Pharmaceutical Science and Clinical Pharmacology, Advisory Committee
March 17
3014512539
Psychopharmacologic Drugs Advisory Committee
To be announced
3014512544
Pulmonary Allergy Drugs Advisory Committee
March 9, March 10, April dates to be announced
3014512545
Reproductive Health Drugs, Advisory Committee
May dates to be announced
3014512537
July 22, September 16
3014512398
CENTER FOR DEVICES AND RADIOLOGICAL HEALTH
Device Good Manufacturing Practice Advisory Committee
Medical Devices Advisory Committee (Comprised of 18 Panels)
Anesthesiology and Respiratory Therapy Devices Panel
April 30, June 23, September 15, November 10
3014512624
Circulatory System Devices Panel
February 25, May 27, September 23, December 8–9
3014512625
Clinical Chemistry and Clinical Toxicology Devices Panel
March 17–18, June 16–17, October 20–21
3014512514
Dental Products Panel
March 23, April 13, May 11, July 13, September 14
3014512518
Ear, Nose, and Throat Devices Panel
February 24, May 19, August 25, November 3–4
3014512522
Gastroenterology-Urology Devices Panel
March 11–12, June 17–18, September 9–10, December 2–3
3014512523
General and Plastic Surgery Devices Panel
February 4–5, May 20–21, August 12–13, November 4–5
3014512519
General Hospital and Personal Use Devices Panel
March 5, July 28–29, November 17–18
3014512520
Hematology and Pathology Devices Panel
January 21–22, April 22–23, July 8–9, October 21–22
3014512515
Immunology Devices Panel
April 26, September 15, December 6
3014512516
Medical Devices Dispute Resolution Panel
Meetings occur as needed
3014510232
Microbiology Devices Panel
March 19, September 23
3014512517
Molecular and Clinical Genetics Panel
April 15, October 5–6
3014510231
Neurological Devices Panel
March 11–12, May 13–4, July 8–9, October 7–8, December
9–10
3014512513
Obstetrics and Gynecology Devices Panel
April 22–23, July 15–16, October 21–22, December 16–17
3014512524
Ophthalmic Devices Panel
February 25–26, April 22–23, June 24–25, October 28–29,
November 18–19
3014512396
Orthopedic and Rehabilitation Devices Panel
March 23, June 9–10, October 13–14, December 1–2
3014512521
Radiological Devices Panel
April 28, July 21, September 15, November 17
3014512526
National Mammography Quality Assurance Advisory Committee
January 25
3014512397
Technical Electronic Product Radiation Safety Standards
Committee
No meeting tentatively scheduled for 2010
3014512399
May 20–21
3014510564
March 18–19
3014512548
mstockstill on DSKH9S0YB1PROD with NOTICES
CENTER FOR FOOD SAFETY AND APPLIED NUTRITION
Food Advisory Committee
CENTER FOR VETERINARY MEDICINE
Veterinary Medicine Advisory Committee
NATIONAL CENTER FOR TOXILOGICAL RESEARCH (NCTR)
VerDate Nov<24>2008
19:01 Dec 29, 2009
Jkt 220001
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
E:\FR\FM\30DEN1.SGM
30DEN1
69122
Federal Register / Vol. 74, No. 249 / Wednesday, December 30, 2009 / Notices
Committee Name
Tentative Date of Meeting(s)
Science Advisory Board to NCTR
Advisory Committee 10-Digit Information Line
Code
November 17–18
3014512559
March, May, July, and November dates to be announced
8732110002
Center for Tobacco
Tobacco Products Scientific Advisory Committee
Dated: December 24, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9–30973 Filed 12–29–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0664]
Second Annual Sentinel Initiative
Public Workshop
AGENCY:
Food and Drug Administration,
HHS.
mstockstill on DSKH9S0YB1PROD with NOTICES
ACTION:
Notice of public workshop.
The Food and Drug Administration
(FDA) is announcing the following
workshop: Second Annual Sentinel
Initiative Public Workshop. This 1-day
workshop, organized and hosted by the
Engelberg Center for Health Care Reform
at Brookings, is supported by a grant
from FDA. This workshop is intended to
communicate the current status and
future vision of active medical product
surveillance activities and explore
stakeholder perspectives on a broad
range of issues. The workshop will
feature a series of presentations on
recently completed FDA contracts to
inform various aspects of the
development of the Sentinel System; an
update on FDA’s ongoing pilot projects
in active surveillance of medical
product safety; and a discussion of three
issues of broad interest: maintaining
patient privacy while conducting
medical product safety surveillance,
developing the Sentinel System as a
national resource for medical product
safety surveillance for others outside of
FDA, and developing a multi-purpose
distributed system that can be used to
conduct safety surveillance,
comparative effectiveness research,
product quality assessment and to
address other types of public health
questions.
Date and Time: The workshop will be
held on January 11, 2010, from 8:30 a.m.
to 4:45 p.m.
VerDate Nov<24>2008
19:01 Dec 29, 2009
Jkt 220001
Location: The workshop will be held
at Marriott Metro Center at 775 12th
Street NW., Washington, DC 20005.
Contact: Kayla Garvin, Center for
Drug Evaluation and Research, Bldg. 22,
rm. 4339, Food and Drug
Administration, 10903 New Hampshire
Ave., Silver Spring, MD 20903, 301–
796–3755, e-mail:
Kayla.Garvin@fda.hhs.gov.
Registration: To attend the workshop,
please register at https://tinyurl.com/
yce6c3z. When registering, provide the
following information: Your name, title,
company or organization (if applicable),
address, phone number, and e-mail
address. There is no fee to register for
the public workshop and because
seating is limited, registration will be on
a first-come, first-served basis. A 1-hour
lunch break is scheduled; however no
food will be provided. There are
multiple restaurants within walking
distance of the hotel where attendees
can purchase lunch. If you need special
accommodations due to a disability,
please contact Brookings’ event
coordinator at 202–797–4391 or by email: sentinelevent@brookings.edu at
least 7 days in advance.
Transcripts: Please be advised that as
soon as a transcript is available, it will
be accessible at https://www.fda.gov/
Safety/FDAsSentinelInitiative/
ucm149341.htm. It may be viewed at the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD. A transcript will also be available
in either hardcopy or on CD–ROM, after
submission of a Freedom of Information
request. Written requests are to be sent
to the Division of Freedom of
Information (HFI–35), Office of
Management Programs, Food and Drug
Administration, 5600 Fishers Lane, rm.
6–30, Rockville, MD 20857.
Dated: December 23, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9–30971 Filed 12–29–09; 8:45 am]
BILLING CODE 4160–01–S
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of meetings of the National
Advisory Allergy and Infectious
Diseases Council.
The meetings will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Allergy and Infectious Diseases Council.
Date: February 1, 2010.
Open: 10:30 a.m. to 11:40 a.m.
Agenda: Report from the Institute Director.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive,
Conference Rooms E1/E2, Bethesda, MD
20892.
Closed: 11:40 a.m. to 12:40 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive,
Conference Rooms E1/E2, Bethesda, MD
20892.
Contact Person: Marvin R. Kalt, PhD,
Director, Division of Extramural Activities,
National Institutes of Health/NIAID, 6700B
Rockledge Drive, MSC 7610, Bethesda, MD
E:\FR\FM\30DEN1.SGM
30DEN1
]]>Agencies
[Federal Register Volume 74, Number 249 (Wednesday, December 30, 2009)]
[Notices]
[Pages 69119-69122]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-30973]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-N-0664]
Advisory Committees; Tentative Schedule of Meetings for 2010
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing a
tentative schedule of forthcoming meetings of its public advisory
[[Page 69120]]
committees for 2010. During 1991, at the request of the Commissioner of
Food and Drugs (the Commissioner), the Institute of Medicine (the IOM)
conducted a study of the use of FDA's advisory committees. In its final
report, one of the IOM's recommendations was for the agency to publish
an annual tentative schedule of its meetings in the Federal Register.
This publication implements the IOM's recommendation.
FOR FURTHER INFORMATION CONTACT: Teresa L. Hays, Advisory Committee
Oversight and Management Staff (HF-4), Food and Drug Administration,
5600 Fishers Lane, Rockville, MD 20857, 301-827-1220.
SUPPLEMENTARY INFORMATION: The IOM, at the request of the Commissioner,
undertook a study of the use of the FDA's advisory committees. In its
final report in 1992, one of the IOM's recommendations was for FDA to
adopt a policy of publishing an advance yearly schedule of its upcoming
public advisory committee meetings in the Federal Register; FDA has
implemented this recommendation. The annual publication of tentatively
scheduled advisory committee meetings will provide both advisory
committee members and the public with the opportunity, in advance, to
schedule attendance at FDA's upcoming advisory committee meetings.
Because the schedule is tentative amendments to this notice will not be
published in the Federal Register. However, changes to the schedule
will be posted on the FDA advisory committees' Internet site located at
https://www.fda.gov/AdvisoryCommittees/default.htm. FDA will continue to
publish a Federal Register notice 15 days in advance of each upcoming
advisory committee meeting, to announce the meeting (21 CFR 14.20).
The following list announces FDA's tentatively scheduled advisory
committee meetings for 2010. You may also obtain up-to-date information
by calling the Advisory Committee Information Line, 1-800-741-8138
(301-443-0572 in the Washington, DC area) and use the appropriate
Information Line Code for the committee in which you are interested.
------------------------------------------------------------------------
Advisory
Tentative Date of Committee 10-
Committee Name Meeting(s) Digit Information
Line Code
------------------------------------------------------------------------
OFFICE OF THE COMMISSIONER
------------------------------------------------------------------------
Pediatric Advisory March 22, June 21-22, 8732310001
Committee September 20-21,
December 6-7
------------------------------------------------------------------------
Risk Communication February 25-26, May 6-7, 8732112560
Advisory Committee August 19-20, November 8-
9
------------------------------------------------------------------------
Science Board to the February 22, May 17, 3014512603
Food and Drug August 16, November 15
Administration
------------------------------------------------------------------------
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH
------------------------------------------------------------------------
Allergenic Products April 30, October 26 3014512388
Advisory Committee
------------------------------------------------------------------------
Blood Products Advisory April 12-13, July 26-27, 3014519516
Committee November 18-19
------------------------------------------------------------------------
Cellular, Tissue and To be announced 3014512389
Gene Therapies Advisory
Committee
------------------------------------------------------------------------
Transmissible Spongiform To be announced 3014512392
Encephalopathies
Advisory Committee
------------------------------------------------------------------------
Vaccines and Related February 22, May 19-20, 3014512391
Biological Products September 15-16,
Advisory Committee November 17-18
------------------------------------------------------------------------
CENTER FOR DRUG EVALUATION AND RESEARCH
------------------------------------------------------------------------
Anesthetic and Life January 28, April 22, 3014512529
Support Drugs Advisory April 23
Committee
------------------------------------------------------------------------
Anti Infective Drugs August and October dates 3014512530
Advisory Committee To be announced
------------------------------------------------------------------------
Antiviral Drugs Advisory To be announced 3014512531
Committee
------------------------------------------------------------------------
Arthritis Advisory May dates To be announced 3014512532
Committee
------------------------------------------------------------------------
Cardiovascular and Renal January 11, March 1, 3014512533
Drugs Advisory April dates to be
Committee announced, July 28, July
29, December 8, December
9
------------------------------------------------------------------------
Dermatologic and To be announced 3014512534
Ophthalmic Drugs
Advisory Committee
------------------------------------------------------------------------
Drug Safety and Risk To be announced 3014512535
Management Advisory
Committee
------------------------------------------------------------------------
Endocrinologic and January 12, January 13, 3014512536
Metabolic Drugs February 24, May 26-27
Advisory Committee
------------------------------------------------------------------------
Gastrointestinal Drugs February 23, November 3014512538
Advisory Committee dates to be announced
------------------------------------------------------------------------
Nonprescription Drugs To be announced 3014512541
Advisory Committee
------------------------------------------------------------------------
Oncologic Drugs Advisory February 10, May 4, May 3014512542
Committee 5, July 20, July 21,
September 1, September
2, December 1, December
2
------------------------------------------------------------------------
[[Page 69121]]
Peripheral and Central March 23, March 24, June 3014512543
Nervous System Drugs dates to be announced
Advisory Committee
------------------------------------------------------------------------
Pharmaceutical Science March 17 3014512539
and Clinical
Pharmacology, Advisory
Committee
------------------------------------------------------------------------
Psychopharmacologic To be announced 3014512544
Drugs Advisory
Committee
------------------------------------------------------------------------
Pulmonary Allergy Drugs March 9, March 10, April 3014512545
Advisory Committee dates to be announced
------------------------------------------------------------------------
Reproductive Health May dates to be announced 3014512537
Drugs, Advisory
Committee
------------------------------------------------------------------------
CENTER FOR DEVICES AND RADIOLOGICAL HEALTH
------------------------------------------------------------------------
Device Good July 22, September 16 3014512398
Manufacturing Practice
Advisory Committee
------------------------------------------------------------------------
Medical Devices Advisory Committee (Comprised of 18 Panels)
------------------------------------------------------------------------
Anesthesiology and April 30, June 23, 3014512624
Respiratory Therapy September 15, November
Devices Panel 10
------------------------------------------------------------------------
Circulatory System February 25, May 27, 3014512625
Devices Panel September 23, December 8-
9
------------------------------------------------------------------------
Clinical Chemistry and March 17-18, June 16-17, 3014512514
Clinical Toxicology October 20-21
Devices Panel
------------------------------------------------------------------------
Dental Products Panel March 23, April 13, May 3014512518
11, July 13, September
14
------------------------------------------------------------------------
Ear, Nose, and Throat February 24, May 19, 3014512522
Devices Panel August 25, November 3-4
------------------------------------------------------------------------
Gastroenterology-Urology March 11-12, June 17-18, 3014512523
Devices Panel September 9-10, December
2-3
------------------------------------------------------------------------
General and Plastic February 4-5, May 20-21, 3014512519
Surgery Devices Panel August 12-13, November 4-
5
------------------------------------------------------------------------
General Hospital and March 5, July 28-29, 3014512520
Personal Use Devices November 17-18
Panel
------------------------------------------------------------------------
Hematology and Pathology January 21-22, April 22- 3014512515
Devices Panel 23, July 8-9, October 21-
22
------------------------------------------------------------------------
Immunology Devices Panel April 26, September 15, 3014512516
December 6
------------------------------------------------------------------------
Medical Devices Dispute Meetings occur as needed 3014510232
Resolution Panel
------------------------------------------------------------------------
Microbiology Devices March 19, September 23 3014512517
Panel
------------------------------------------------------------------------
Molecular and Clinical April 15, October 5-6 3014510231
Genetics Panel
------------------------------------------------------------------------
Neurological Devices March 11-12, May 13-4, 3014512513
Panel July 8-9, October 7-8,
December 9-10
------------------------------------------------------------------------
Obstetrics and April 22-23, July 15-16, 3014512524
Gynecology Devices October 21-22, December
Panel 16-17
------------------------------------------------------------------------
Ophthalmic Devices Panel February 25-26, April 22- 3014512396
23, June 24-25, October
28-29, November 18-19
------------------------------------------------------------------------
Orthopedic and March 23, June 9-10, 3014512521
Rehabilitation Devices October 13-14, December
Panel 1-2
------------------------------------------------------------------------
Radiological Devices April 28, July 21, 3014512526
Panel September 15, November
17
------------------------------------------------------------------------
National Mammography January 25 3014512397
Quality Assurance
Advisory Committee
------------------------------------------------------------------------
Technical Electronic No meeting tentatively 3014512399
Product Radiation scheduled for 2010
Safety Standards
Committee
------------------------------------------------------------------------
CENTER FOR FOOD SAFETY AND APPLIED NUTRITION
------------------------------------------------------------------------
Food Advisory Committee May 20-21 3014510564
------------------------------------------------------------------------
CENTER FOR VETERINARY MEDICINE
------------------------------------------------------------------------
Veterinary Medicine March 18-19 3014512548
Advisory Committee
------------------------------------------------------------------------
NATIONAL CENTER FOR TOXILOGICAL RESEARCH (NCTR)
------------------------------------------------------------------------
[[Page 69122]]
Science Advisory Board November 17-18 3014512559
to NCTR
------------------------------------------------------------------------
Center for Tobacco
------------------------------------------------------------------------
Tobacco Products March, May, July, and 8732110002
Scientific Advisory November dates to be
Committee announced
------------------------------------------------------------------------
Dated: December 24, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9-30973 Filed 12-29-09; 8:45 am]
BILLING CODE 4160-01-S
